Table: q1_q4_2019_prescription_drugs_intro_to_market , manufacturer_name like Z*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

manufacturer_name	ndc_number	drug_product_description	date_introduced_to_market	wac_at_introduction	marketing_pricing_plan_description	marketing_pricing_plan_non_public_indicator	estimated_number_of_patients	breakthrough_therapy_indicator	priority_review_indicator	acquisition_date	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	general_comments	supporting_documents
Zydus Pharmaceuticals (USA) Inc.	70710102108	Albendazole 200mg Tablets	2019-01-18	366.2800	None	1	0	None	None	None	0.0000	None	None	This is an AB rated generic product that was developed by Zydus.	None
Zydus Pharmaceuticals (USA) Inc.	70710117903	Ambrisentan 5mg Tablets	2019-04-15	2500.0000	None	1	0	None	None	None	0.0000	None	None	This is an AB rated generic product that was developed by Zydus.	None
Zydus Pharmaceuticals (USA) Inc.	70710118003	Ambrisentan 10mg Tablets	2019-04-15	2500.0000	None	1	0	None	None	None	0.0000	None	None	This is an AB rated generic product that was developed by Zydus	None
Zydus Pharmaceuticals (USA) Inc.	70710101401	Phytonadione 5mg Tablet	2019-03-01	5358.9100	None	1	0	None	None	None	0.0000	None	None	This is an AB rated generic product that was developed by Zydus	None
Zydus Pharmaceuticals (USA) Inc.	68382044614	Bosentan 62.5mg Tablet	2019-06-03	10038.5400	None	1	0	None	None	None	0.0000	None	None	This is an AB rated generic product that was developed by Zydus. As Zydus manufactures generic products, we do not estimate the number of patients that may be prescribed our products. We manufacture volume based on an estimated market share along with IQVIA EUTRx data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level.	None
Zydus Pharmaceuticals (USA) Inc.	68382044714	Bosentan 125mg Tablet	2019-06-03	10038.5400	None	1	0	None	None	None	0.0000	None	None	This is an AB rated generic product that was developed by Zydus. As Zydus manufactures generic products, we do not estimate the number of patients that may be prescribed our products. We manufacture volume based on an estimated market share along with IQVIA EUTRx data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level.	None
Zydus Pharmaceuticals (USA) Inc.	70710120301	Trientine HCl 250mg Capsules	2019-05-29	15618.3400	None	1	0	None	None	None	0.0000	None	None	This is an AB rated generic product that was developed by Zydus. As Zydus manufactures generic products, we do not estimate the number of patients that may be prescribed our products. We manufacture volume based on an estimated market share along with IQVIA EUTRx data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level.	None
Zydus Pharmaceuticals (USA) Inc.	70710161006	Arsenic Trioxide Inj 12mg/6ml (10x6ml)	2019-09-16	7698.2400	None	1	0	None	None	None	None	None	None	This is an AP rated injectable generic product that was developed by Zydus. Acquisition date and price are not applicable. Additionally, as Zydus manufactures generic products, we do not estimate the number of patients that may be prescribed our products neither by state or nationally. We manufacture volume based on an estimated market share along with IQVIA EUTRx data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients.	None
Zydus Pharmaceuticals (USA) Inc.	70710127703	Deferasirox Tab 90mg 30 Count	2019-11-21	1093.3000	None	1	None	None	None	None	None	None	None	This is an AB rated generic product that was developed by Zydus. Acquisition date and price are not applicable. Additionally, as Zydus manufactures generic products, we do not estimate the number of patients that may be prescribed our products neither by state or nationally. We manufacture volume based on an estimated market share along with IQVIA EUTRx data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients.	None
Zydus Pharmaceuticals (USA) Inc.	70710115201	Isosorbide Dinitrate Tab 40mg 100 Ct	2019-12-11	1335.3700	None	1	None	None	None	None	None	None	None	This is an AB rated generic product that was developed by Zydus. Acquisition date and price are not applicable. Additionally, as Zydus manufactures generic products, we do not estimate the number of patients that may be prescribed our products neither by state or nationally. We manufacture volume based on an estimated market share along with IQVIA EUTRx data and/or usages provided by our customers. Our manufactured volumes are based on national level data and we do not break these estimates down to a patient or state level. If IQVIA has a data point that states an estimated number of patients, it is not data that Zydus subscribes to. Zydus feels that by entering IQVIA TRx data into "Estimated Number of Patients" column, it would be a misrepresentation of IQVIA's data as TRx is defined as the counts of total (new plus refill) prescriptions dispensed by pharmacists and not as the estimated number of patients.	None